



## Evidence-based indications for the use of PET-CT in the United Kingdom 2016

The Royal College of Radiologists, Royal College of Physicians of London, Royal College of Physicians and Surgeons of Glasgow, Royal College of Physicians of Edinburgh, British Nuclear Medicine Society, Administration of Radioactive Substances Advisory Committee



Royal College  
of Physicians



RCR

The Royal College of Radiologists

# Contents

---

<b>Foreword</b>	<b>1</b>	<b>Non-FDG tracers for clinical practice</b>	<b>10</b>
		Indications for non-FDG tracers	10
<b>Indications for 18F-fluorodeoxyglucose (FDG)</b>			
<b>PET-CT</b>	<b>3</b>	<b>Key references</b>	<b>13</b>
Oncology applications	3	Indications for FDG scans	13
Non-oncological applications	8	Indications for non-FDG scans	25

## Foreword

---

Since its introduction into clinical practice in the UK 26 years ago, positron emission tomography (PET) followed by positron emission tomography-computed tomography (PET-CT) has become a key investigative tool in the assessment of cancer and non-cancer medical conditions. The Inter-Collegiate Standing Committee on Nuclear Medicine (ICSCNM) supported the development of PET-CT in the UK through a number of initiatives including the 2003 document *Positron emission tomography – A strategy for provision in the UK*, the forerunner of the publication *PET-CT in the UK. A strategy for development and integration of a leading edge technology within routine clinical practice in the UK*.

The publication of the first version of *Evidence-based indications for the use of PET-CT in the United Kingdom 2012* was a landmark ICSCNM document. Authored by Sally Barrington and Andrew Scarsbrook, it provided, for the first time, a guide to the use of PET-CT in clinical practice and the evidence-base on which this was founded. It was used widely to inform and to shape the commissioning of PET-CT services in the UK and beyond. Now in its third edition, the 2016 version builds on the evidence cited in earlier editions providing an updated review with key references for the use of fluorodeoxyglucose (FDG) and non-FDG PET-CT tracers in malignant and in non-malignant disease. The ICSCNM wish to thank Andrew Scarsbrook and Sally Barrington for updating this invaluable reference guide.

Brian Neilly

Chair ICSCNM

A document prepared for the Intercollegiate Standing Committee on Nuclear Medicine, by members of The Royal College of Radiologists and the Royal College of Physicians.

**Lead Authors:** Andrew Scarsbrook and Sally Barrington

This guidance comprises an up-to-date summary of relevant indications for the use of PET-CT, where there is good evidence that patients will benefit from improved disease assessment resulting in altered management and improved outcomes. This document supersedes the previous Evidence based Indications for the use of PET-CT in the United Kingdom guidance published by The Royal College of Physicians in December 2013. New indications and key references are highlighted in red ink for ease of identification. The document will be updated at regular intervals.

The indications are divided into oncological and non-oncological applications then body area/system. This list is not exhaustive and there are cases where PET-CT may be helpful in patients who have equivocal or definite abnormalities on other imaging where PET-CT may alter the management strategy if found to be 'positive' or 'negative'; for example, radical or high-risk surgery. PET-CT would be appropriate in such patients at the discretion of the local Administration of Radioactive Substances Advisory Committee (ARSAC) certificate holder.

## Indications for 18F-fluorodeoxyglucose (FDG) PET-CT

### Oncology applications

#### Brain

- Identifying the grade of malignancy where there is uncertainty on anatomical imaging and functional assessment would assist biopsy.
- Suspected relapse where magnetic resonance (MR) is equivocal to inform decisions regarding surgery or radiotherapy planning – see below for alternative PET imaging with 11-Carbon (<sup>11</sup>C)-methionine or <sup>18</sup>F-fluoroethyltyrosine (FET).
- Assessment of suspected high-grade transformation in low-grade glioma.
- Differentiation of cerebral tumour from atypical infection in immuno-compromised patients with indeterminate lesions on MR/CT.

#### Head and neck tumours

- Staging of patients where staging is difficult clinically; for example, where there is uncertainty on other imaging or equivocal findings that would preclude radical treatment.
- Staging or restaging of patients with a high risk of disseminated disease such as advanced loco-regional disease and primary sites with a high propensity for disseminated disease such as nasopharyngeal cancer.
- To identify the primary site in patients presenting with metastatic squamous cell carcinoma in cervical lymph nodes, with no primary site identified on other imaging.
- Response assessment 3–6 months' post chemo-radiotherapy.
- To differentiate relapse from treatment effects in patients suspected to have tumour recurrence where magnetic resonance imaging (MRI) is uncertain or equivocal.

#### Thyroid carcinoma

- Assessment of patients with elevated thyroglobulin levels and negative iodine scintigraphy with suspected recurrent disease.
- To evaluate disease in treated medullary thyroid carcinoma associated with elevated calcitonin levels with equivocal or normal cross-sectional imaging, bone and octreotide scintigraphy – see below for alternative PET imaging with 68 Gallium (<sup>68</sup>Ga)-DOTA-octreotate (DOTATATE), DOTA-1-NaI3-octreotide (DOTANOC) or DOTA-octreotide (DOTATOC).

#### Lung carcinoma

- Staging of patients considered for radical treatment of non-small cell lung cancer:
  - Specifically National Institute for Health and Care Excellence (NICE) guidelines (2011) recommend PET-CT is used for mediastinal lymph node staging in patients whose disease is potentially suitable for treatment with curative intent, such as those with a low probability of mediastinal malignancy (lymph nodes <1 centimetre [cm] on CT) or in patients with an intermediate probability of mediastinal metastases (nodes between 1–2 cm on CT) and for confirming distant metastases.

- Characterisation of a solid solitary pulmonary nodule with an initial risk of malignancy of >10% (Brock model) where the nodule size is greater than local PET-CT detection threshold (8–10 millimetres [mm]) below which the influence of the partial volume effect is substantial and precludes adequate sensitivity:
  - Especially in the case of failed biopsy, a technically difficult biopsy or where there is a significant risk of a pneumothorax in patients with medical co-morbidities.
  - Smaller nodules in the upper lobes may be considered after discussion with the local ARSAC certificate holder if biopsy and/or CT follow-up are not appropriate.
- Assessment of response to chemotherapy and/or radiation treatment in selected patients who have had an apparently very good response on conventional imaging and surgery is being considered.
- Assessment of suspected disease recurrence:
  - To differentiate between treatment effects and recurrent cancer.
- Staging of patients with small-cell lung cancer with limited disease on CT being considered for radical therapy.

#### **Pleural malignancy**

- To guide biopsy in patients with suspected pleural malignancy:
  - With pleural thickening; FDG is less likely to be useful in patients presenting with a pleural effusion only or with a history of previous pleurodesis.
- To exclude extra-thoracic disease in proven mesothelioma in patients considered for multimodality treatment including radical surgery/decortication.

#### **Thymic tumours**

- Staging of patients considered for surgical resection.
- Assessment of indeterminate thymic lesions if being considered for radical treatment.

#### **Oesophago-gastric carcinoma**

- Staging/restaging of patients with oesophageal or oesophago-gastric carcinoma, suitable for radical treatment, including patients who have received neo-adjuvant treatment.
- Evaluation of suspected recurrence of oesophago-gastric tumours when other imaging is negative or equivocal.

#### **Gastrointestinal stromal tumours**

- Staging prior to treatment in patients who are likely to require systemic therapy.
- Response assessment to systemic therapy.

#### **Breast carcinoma**

- Assessment of multi-focal disease or suspected recurrence in patients with dense breasts.
- Differentiation of treatment-induced brachial plexopathy from tumour infiltration in symptomatic patients with an equivocal or normal MR.
- Assessment of extent of disease in selected patients with disseminated breast cancer before therapy.
- Assessment of response to chemotherapy in patients whose disease is not well demonstrated using other techniques; for example, bone metastases.

### Hepato-pancreatico-biliary cancers

- Staging of patients with potentially operable pancreatic adenocarcinoma where cross-sectional imaging is equivocal for metastatic disease and a positive PET-CT would lead to a decision not to operate.
- Staging of potentially operable primary hepato-biliary malignancy (cholangiocarcinoma, gallbladder carcinoma or hepatocellular carcinoma) where cross-sectional imaging is equivocal for metastatic disease, who are fit for resection and a positive PET-CT would lead to a decision not to operate.
- Suspected recurrence of hepato-pancreatico-biliary cancer in selected patients, where other imaging is equivocal or negative, taking into consideration that up to 30% of pancreatic adenocarcinomas and up to 50% of differentiated hepatocellular carcinomas may not be FDG avid.

See below for other tracers that may be helpful in staging.

### Colorectal carcinoma

- Staging of patients with synchronous metastases at presentation suitable for resection or patients with equivocal findings on other imaging; for example, pulmonary or liver lesions.
- Restaging of patients with recurrence being considered for radical treatment and/or **invasive targeted techniques (for example, metastatectomy/selective internal radiation therapy [SIRT])**.
- **Assessment of treatment response in patients with rectal carcinoma post (chemo)radiotherapy with indeterminate findings on other imaging.**
- **Assessment of treatment response following targeted therapy (ablative techniques for liver or lung metastases, selective internal radiotherapy for liver metastases) in metastatic colorectal carcinoma when findings on other imaging are inconclusive.**
- Detection of recurrence in patients with rising tumour markers and/or clinical suspicion of recurrence with normal or equivocal findings on other imaging.
- Evaluation of indeterminate pre-sacral masses post-treatment.

### Urological malignancy

- Assessment of metastatic renal and ureteric carcinoma in difficult management situations or when standard imaging is inconclusive.
- Assessment of renal carcinoma at staging in selected cases with equivocal findings on other imaging (recognising that ~50% of renal cell carcinoma may not be FDG avid and that the tracer is excreted into the urinary tract).
- Assessment of advanced muscle-invasive bladder carcinoma, which is potentially radically treatable.

*See below for alternative PET imaging with non-FDG tracers in prostate malignancy.*

### Gynaecological malignancy

- Staging or restaging of patients with vulval or uterine (cervix/endometrium) carcinoma considered for exenterative surgery.
- Staging and restaging of patients with locally advanced cervical cancer being considered for radical chemo-radiotherapy.
- **Response assessment of locally advanced cervical cancer after chemoradiotherapy.**
- Suspected recurrence of vulval, endometrial or cervical carcinoma when other imaging is equivocal.
- Detection of tumour in selected patients with ovarian carcinoma who have rising CA125 levels and equivocal or negative imaging.

### Testicular malignancy

- Assessment of recurrent disease in patients with metastatic seminoma or teratoma with elevated or rising tumour markers and equivocal or normal anatomical imaging.
- Evaluation of residual masses for patients with seminoma and teratoma, although mature differentiated teratoma may not be FDG avid and cannot be excluded with a negative scan.

### Anal and penile carcinoma

- Staging of selected patients considered for radical treatment.

### Lymphoma

- Staging of FDG-avid lymphomas.
- Remission assessment of FDG-avid lymphomas after completion of treatment using the five-point scale (Deauville criteria) for response assessment. If there has been a complete metabolic response (CMR) on an interim scan, an end of treatment scan is not required.
- Interim assessment to guide response adapted treatment in selected patients with Hodgkin lymphoma
- Interim assessment to monitor treatment if mid-therapy imaging is performed and to exclude progression in patients with aggressive non-Hodgkin Lymphoma
- Evaluation of suspected relapse for FDG-avid lymphomas in symptomatic patients. *Surveillance imaging is not recommended.*
- Assessment of response to second line treatment and subsequent treatments for FDG-avid lymphoma.
- Staging of suspected post-transplant lympho-proliferative disorder (PTLD).
- Prior to bone marrow transplant to assess remission status and residual volume of disease and suitability for transplant.
- To determine extent and identify a suitable biopsy site in patients with low-grade lymphomas in who there is suspected high-grade transformation.

### Myeloma

- FDG PET/CT has prognostic value when used in the initial diagnosis of myeloma, but there is currently insufficient evidence to justify the routine use of PET/CT in all cases of newly diagnosed myeloma. Use in selected patients as follows:
  - To identify patients with smouldering myeloma at high risk of progression to symptomatic disease requiring initiation of treatment in line with revised International Myeloma Working Group Criteria
  - Baseline assessment in patients with non-secretory and oligo-secretory myeloma as a baseline for subsequent response assessment
  - Assessment of patients with apparently solitary plasmacytoma to exclude other sites of disease
  - To assess response or suspected relapse in patients with oligo-secretory or non-secretory myeloma, patients with predominantly extra-medullary disease and patients with solitary plasmacytoma
  - Remission assessment post stem-cell transplantation in patients with absence of para-proteins or light chains in blood, urine and bone marrow in selected cases
  - Assessment of patients with monoclonal gammopathy associated neuropathies (MGAN) to identify plasmacytomas which may be amenable to radiotherapy.



### Skin tumours

- Staging of patients with known disseminated melanoma to assess extent of disease prior to treatment.
- To assess for distant disease in patients with melanoma when radical dissection is contemplated (nodal or metastatic disease).
- 
- To assess response to isolated limb infusion for malignant melanoma.
- **In the assessment of selected patients with Merkel Cell Carcinoma to more accurately stage disease extent where this would alter intended management and for assessment of treatment response and/or suspected recurrence when conventional imaging is inconclusive.**
- To exclude systemic involvement in skin lymphomas **and exclude large cell transformation in Mycosis Fungoides.**
- To exclude primary malignancy where dermatomyositis suspected to represent a paraneoplastic manifestation.

*Not indicated for early-stage patients who should undergo sentinel node biopsy.*

### Musculoskeletal tumours

- Assessment of suspected malignant transformation within plexiform neurofibromas in patients with neurofibromatosis type 1 with delayed imaging recommended at four hours where there is uptake at 60–90 minutes.
- Staging of high-grade sarcomas, unless already proven to have metastatic disease, especially Ewing's sarcoma, rhabdomyosarcoma, leiomyosarcoma, osteosarcoma, malignant fibrous histiocytoma, synovial sarcoma and myxoid liposarcoma.
- Pre-amputation in the setting of a high-grade sarcoma where the detection of distant disease will alter the surgical management.
- To stage patients with metastatic sarcoma considered for liver or lung metastatectomy where anatomical imaging has not identified any extra-thoracic or extra-hepatic disease which would preclude surgery.
- Response assessment in high-grade sarcomas.

### Paraneoplastic syndromes

- To detect an occult primary tumour in selected patients with non-metastatic manifestations of neoplastic disease when other imaging is negative or equivocal.

### Carcinoma of unknown primary

- Detection of the primary site when imaging and histopathology has failed to show a primary site, where the site of tumour will influence choice of chemotherapy.

### Neuroendocrine tumours

- Staging or restaging of selected patients with poorly differentiated neuroendocrine tumours prior to treatment with negative or normal metaiodobenzylguanidine (mIBG) and octreotide scans.
- Assessment of possible multifocal disease in patients with paraganglioma considered for surgery.
- **Assessment of selected patients with adrenocortical carcinoma being considered for invasive treatment where cross-sectional imaging is inconclusive.**

### Rare tumours in children and young adults

- Staging of osteosarcoma and response to chemotherapy.
- Staging and response assessment of Ewing's sarcoma.
- PET-CT may be helpful on an individual case basis in paediatric or adolescent patients with:
  - Wilms' tumours
  - Metaiodobenzylguanidine (MIBG)-negative neuroblastoma
  - **Rhabdomyosarcoma**
  - Hepatoblastoma
  - Langerhans' cell histiocytosis.

### Non-oncological applications

#### Neurological applications

- Pre-surgical assessment of medically refractory complex partial seizures where MR is normal, equivocal or conflicts with electroencephalogram (EEG) localisation.
- Evaluation of memory loss/neurological signs suggestive of dementia and differentiation of types of dementia in selected patients.

See below for amyloid imaging which may be helpful in highly selected patients with suspected dementia.

#### Cardiological indications

- Assessment of myocardial viability in patients with ischaemic heart failure and poor left ventricular function being considered for revascularisation, usually in combination with perfusion imaging with sestamibi/tetrofosmin or ammonia/rubidium.

#### Vasculitis

- Evaluation of suspected vasculitis in selected cases; for example, to determine the extent and distribution of the disease activity or to exclude underlying malignancy which may be a paraneoplastic phenomenon, resulting in atypical presentations of vasculitis.
- PET-CT would not be indicated in all patients with giant cell arteritis but is of use in patients where conventional investigations are unhelpful and treatment would be altered if ongoing inflammatory disease is confirmed.

#### Sarcoidosis

- Assessment of activity and distribution of disease at baseline in highly selected cases where there is diagnostic uncertainty using conventional imaging (for example, suspected cardiac sarcoidosis. **May be used in combination with perfusion imaging to assess known or suspected cardiac inflammation in patients with known or suspected sarcoidosis after prolonged fasting**).
- Assessment of disease response where other measures to monitor response are unhelpful and/or in patients with disease resistant to treatment.

#### Infection imaging

- Detection of site of focal infection in immuno-compromised patients or problematic cases of infection.
- Evaluation of vascular graft **or cardiac implantable device related** infection in selected cases provided sufficient time has elapsed since surgery.

**Pyrexia of unknown origin (PUO)**

- To identify the cause of a PUO where conventional investigations have not revealed a source.

## Non-FDG tracers for clinical practice

The role of FDG in a range of malignancies is established, but there are limitations to using FDG for imaging some tumours. Non-FDG tracers can be used to image a limited number of tumours, which are important for patient care. The exceptions are the potential use of choline derivatives for imaging prostate cancer and the use of amyloid tracers for assessment of patients with cognitive impairment/dementia.

Fluorinated tracers can be produced in a regional cyclotron and transported, such as FDG and fluoro-choline. Generators that are used to produce radionuclides such as  $^{68}\text{Ga}$  Gallium can be purchased and the tracers produced in nuclear medicine department radiopharmacies. Other short-lived tracers such as  $^{13}\text{N}$ -ammonia and  $^{11}\text{C}$ -Carbon-labelled compounds are produced in a cyclotron which needs to be on the same site as the scanner.

It is recognised that cyclotron and generator-produced tracers are available in a few specialist centres and that fluorinated tracers **and generator-produced tracers** may become more widely available. The rationale for using alternative tracers to FDG for these indications is highlighted in italics.

### Indications for non-FDG tracers

#### **$^{11}\text{C}$ -Methionine (cyclotron-produced short-lived tracer) or $^{18}\text{F}$ -Fluoroethyltyrosine (FET)**

$^{11}\text{C}$ -Methionine **and  $^{18}\text{F}$ -FET** are superior in defining the extent of tumour in low and intermediate grade gliomas compared to FDG, which has limited use because of high uptake in normal brain.

- Assessment of tumour grade and extent in some patients with glioma for staging or suspected recurrence to target biopsy and plan treatment.

*$^{11}\text{C}$ -Methionine has been reported as having better sensitivity for localising parathyroid tumour than FDG in difficult cases.*

- Parathyroid tumour localisation in difficult cases where the tumour has not been found using conventional anatomical and functional imaging techniques.

#### **$^{13}\text{N}$ -Ammonia (cyclotron-produced short-lived tracer) $^{82}\text{Rb}$ -Rubidium chloride (generator-produced short-lived tracer)**

- Assessment of myocardial perfusion in patients with suspected ischaemic heart disease or to assess the extent of disease in patients with known coronary artery disease (CAD) **or in combination with FDG for assessment of cardiac sarcoidosis (as above).**
- Assessment of perfusion in selected patients with coronary anomalies with congenital disease, after surgery and with Kawasaki's disease.

*$^{99\text{m}}\text{Tc}$ -Methyl diphosphonate ( $^{99\text{m}}\text{Tc}$ )-labelled tracers (sestamibi, tetrofosmin) are widely available and have high sensitivity and specificity for the evaluation of CAD with Single-photon emission computed tomography (SPECT). However, PET tracers have improved sensitivity in some situations, for example, in high-body mass patients where significant attenuation of the inferior and anterior walls limits assessment.  $^{13}\text{N}$ -Ammonia allows quantitative assessment of myocardial perfusion to be performed and is better used to assess disease in patients with balanced three vessel disease. Rubidium has improved image quality compared to Technetium  $^{99\text{m}}\text{Tc}$  and may be cost-effective compared to  $^{99\text{m}}\text{Tc}$  when there is a large throughput of patients (around five cases per day Monday to Friday). Both PET tracers are associated with lower radiation dose than  $^{99\text{m}}\text{Tc}$  tracers.*

**<sup>11</sup>C-Choline or <sup>18</sup>F-fluoro-choline (both cyclotron-produced but <sup>11</sup>C short-lived, <sup>18</sup>F can be transported) and <sup>68</sup>Ga-prostate-specific membrane antigen (PSMA)**

*FDG is not taken up by most prostate cancers. FDG is taken up but rapidly dephosphorylated and 'washes out' of the liver and is not useful to image up to 50% of hepatocellular carcinoma (HCC). Choline transport and choline kinase enzymes are over expressed in many malignancies including prostate cancer and HCC. A substantial number of observational studies support the use of choline PET-CT to detect local and distant metastatic disease in prostate cancer with improved accuracy compared to CT and MR. <sup>11</sup>C-Choline is generally preferred to <sup>18</sup>F-fluorocholine because it is not excreted in urine but has limited availability. There are two forms of <sup>18</sup>F-fluorocholine available (fluoro-methyl choline and fluoro-ethyl choline) and neither has undergone validation in direct comparison with <sup>11</sup>C-choline. <sup>68</sup>Gallium-PSMA (Prostate Specific Membrane Antigen) is a rapidly emerging alternative tracer for assessment of prostate malignancy with superior diagnostic accuracy compared to choline.*

- Evaluation of high-risk patients before curative treatment or to evaluate equivocal findings on conventional imaging such as possible nodal or metastatic disease in patients with prostate cancer where confirmation or exclusion of distant disease would directly influence patient management.
- Suspected recurrence in patients with a rapidly rising prostate-specific antigen (PSA) and negative or equivocal conventional imaging where the results would directly influence patient management.

*There is evidence from observational studies suggesting <sup>18</sup>F-fluorocholine improves the accuracy of HCC detection in primary staging and recurrence. Liver transplantation can offer some patients a chance of cure but careful pre treatment assessment is essential.*

- Assessment of patients with HCC being considered for transplant or other radical treatment where the results would directly influence patient management.

**<sup>11</sup>C-acetate**

- Assessment of HCC.

*The combination of FDG and acetate for HCC has been demonstrated to identify more abnormalities to stage the disease than conventional imaging.*

**<sup>68</sup>Ga-labelled somatostatin receptor (SSR) imaging (generator produced)**

- Staging and assessment of suspected recurrence in neuroendocrine tumours (NETs).

*Most NETs have low uptake of FDG; however, tracers that bind to somatostatin receptors, which are expressed by these tumours have high uptake. Somatostatin receptor (SSR) scintigraphy using SPECT tracers, for example <sup>111</sup>In-octreotide, have been in clinical use for a number of years. Newer peptides labelled with <sup>68</sup>Ga such as DOTATOC and DOTATATE show much higher affinity for NETs. Recently radionuclide treatments using SSR agents have resulted in improved quality of life and survival for patients with NETs and SSR imaging helps to select and manage patients for radionuclide therapy.*

**<sup>18</sup>F-FluoroDOPA (f-dopa) (cyclotron-produced but transportable)**

- Assessment of suspected congenital hyperinsulinism.
- Assessment in selected cases of NETs.

*There is evidence that F-DOPA may have high uptake in some NETs, mainly carcinoids, and it can be useful to guide surgery in cases of suspected congenital hyperinsulinism.*

**<sup>18</sup>F-Fluoride bone imaging (cyclotron-produced but transportable)**

- Assessment of benign and malignant diseases of bone in selected patients.

Sodium  $^{18}\text{F}$ -fluoride produces very high-quality images of the skeleton with high uptake in bone and rapid clearance from blood.  $^{18}\text{F}$ -Fluoride has been evaluated against  $^{99\text{m}}\text{Tc}$ -MDP planar and SPECT imaging in patients with suspected or known metastatic bone disease. These studies show it to be more sensitive and specific than  $^{99\text{m}}\text{Tc}$ -MDP scintigraphy, and the addition of CT increases further the specificity of the test.

Uptake times are shorter than conventional bone scintigraphy, 15–30 minutes versus 3–4 hours, and imaging times are shorter 15–30 minutes versus 30–60 minutes suggesting that  $^{18}\text{F}$ -fluoride imaging for some patients with bone disease may be an appropriate use of PET-CT.

**$^{18}\text{F}$ -labelled Amyloid tracer brain imaging (Florbetapir [Amyvid], Florbetaben [Neuraceq], Flutemetamol [Viazmyl]) (cyclotron-produced but transportable)**

- Use in highly selected patients with cognitive impairment where i) Alzheimers dementia (AD) is a possible diagnosis but this remains uncertain after comprehensive evaluation by a dementia expert and conventional imaging work-up and ii) where knowledge of the presence or absence of amyloid is expected to increase diagnostic certainty and influence patient management.
- *Currently there is a paucity of evidence of the impact of these tracers on clinical outcomes and the above indication is based on appropriate use criteria developed by the Society of Nuclear Medicine and Molecular Imaging and the Alzheimer's Association. Amyloid PET imaging detects the presence of human amyloid deposition in the brain. While amyloid plaques are one of the defining pathological features of AD, it is not specific and can be present as part of the normal ageing process and in other clinical syndromes. As a result it is essential that this test is only used in patients who have been fully assessed by an expert clinician and it is considered that amyloid imaging can contribute to diagnosis in combination with clinical assessment and other factors.*
- *Currently there is insufficient evidence to support the use of this technique except in the scenario defined above where the patient has persistent or progressive unexplained memory impairment confirmed by standard medical tests, an unusual clinical presentation and/or an atypically early age of onset.*
- *Inappropriate scenarios for use would include patients 65 years or older who meet standard definitions and tests for AD; where there is no clinical evidence of memory impairment (that is, as a screening tool); to assess the severity of dementia; in asymptomatic patients with a family history of dementia; for non-medical reasons such as pre-employment screening.*

## Key references

---

### Indications for FDG scans

#### General overview

Hillner BE, Siegel BA, Lui D *et al.* Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. *J Clin Oncol* 2008; **26**: 2155–2161.

The Royal College of Radiologists. *iRefer: Making the best use of clinical radiology, 7th edition*. London: The Royal College of Radiologists, 2012.

US Department of Health & Human Services. Agency for Healthcare Research & Quality Technology Assessment, National coverage determination for PET scans. [www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=211&ncdver=5&bc=AgAAgAAAAAAAAA==&](http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=211&ncdver=5&bc=AgAAgAAAAAAAAA==&) (Last accessed 18/04/2016)

#### Brain tumours

Chen W. Clinical applications of PET in brain tumors. *J Nucl Med* 2007; **48**: 1468–1481.

Gómez-Río M, Rodríguez-Fernández A, Ramos-Font C, López-Ramírez E, Llamas-Elvira JM. Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence. *Eur J Nucl Med Mol Imaging* 2008; **35**: 966–975.

Hillner BE, Siegel BA, Shields AF *et al.* Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry. *Mol Imaging Biol* 2011; **13**: 161–165.

O'Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. *J Nucl Med* 1997; **38**: 1575–1583.

Van Laere K, Ceysens S, Van Calenbergh F *et al.* Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. *Eur J Nucl Med Mol Imaging* 2005; **32**: 39–51.

#### Head and neck tumours

Rohde M, Dyrvig AK, Johansen J *et al.* 18F-fluoro-deoxy-glucose positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis. *Eur J Cancer* 2014; **50**: 2271–2279.

Kim SY, Roh JL, Yeo NK *et al.* Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. *Ann Oncol* 2007; **18**: 1698–1703.

Krabbe CA, Pruijm J, van der Laan BF, Rödiger LA, Roodenburg JL. FDG PET and detection of distant metastases and simultaneous tumours in head and neck squamous cell carcinoma: a comparison with chest radiography and chest CT. *Oral Oncol* 2009; **45**: 234–240.

Kubicek GJ, Champ C, Fogh S *et al.* FDG-PET staging and importance of lymph node SUV in head and neck cancer. *Head Neck Oncol* 2010; **2**: 19.

Lonneux M, Hamoir M, Reyckers H *et al.* Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. *J Clin Oncol* 2010; **28**: 1190–1195.

Cacicedo J, Fernandex I, Del Hoyo O *et al.* Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis. *Eur J Nucl Med Mol Imaging* 2015; **42**: 1378–1389.

Zhu L, Wang N. 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis. *Surg Oncol* 2013; **22**: 190–194.

Smith KA, Dort JC, Hall SF, Rudmik L. Cost-effectiveness of positron emission tomography-CT in the evaluation of cancer of unknown primary of the head and neck. *Head Neck* 2015; **37**: 1781–1787.

Scott AM, Gunawardana DH, Bartholomeusz D, Ramshaw J, Lin P. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study. *J Nucl Med* 2008; **49**: 1593–6100.

Porceddu SV, Pryor DI, Burmeister E *et al.* Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. *Head Neck* 2011; **33**: 1675–1682.

Yao M, Smith RB, Hoffman HT *et al.* Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. *Int J Radiat Oncol Biol Phys* 2009; **74**: 9–14.

Senft A, de Bree R, Hoekstra OS *et al.* Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. *Radiother Oncol* 2008; **87**: 221–229.

Shah K, Te Marvelde L, Collins M *et al.* Safety and cost analysis of an (18)FDG PET-CT response based follow-up strategy for head and neck cancers treated with primary radiation or chemoradiation. *Oral Oncol* 2015; **51**: 529–535.

Sheikhabahaei S, Taghipour M, Ahmad R *et al.* Diagnostic Accuracy of follow-up FDG PET or PET/CT in patients with head and neck cancer after definitive treatment: a systematic review and meta-analysis. *AJR Am J Roentgenol* 2015; **205**: 629–639.

Mehanna H, Wong W, McConkey CC *et al.* PET-CT surveillance versus neck dissection in advanced head and neck cancer. *N Engl J Med* 2016; **374**: 1444–1454.

### Thyroid carcinoma

Abraham T, Schöder H. Thyroid cancer – indications and opportunities for positron emission tomography/computed tomography imaging. *Semin Nucl Med* 2011; **41**: 121–138.

Hooft L, Hoekstra OS, Devillé W *et al.* Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. *J Clin Endocrinol Metab* 2001; **86**: 3779–3786.

Palmedo H, Bucerius J, Joe A *et al.* Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. *J Nucl Med* 2006; **47**: 616–624.

Caetano R, Bastos CR, de Oliveira IA *et al.* Accuracy of positron emission tomography and PET-CT in the detection of differentiated thyroid cancer recurrence with negative <sup>131</sup>I whole-body scan results: A meta-analysis. *Head Neck* 2016; **38**: 316–327.

Szakáll S Jr, Esik O, Bajzik G *et al.* 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. *J Nucl Med* 2002; **43**: 66–71.



### Lung carcinoma

National Institute for Health and Clinical Excellence. The diagnosis and treatment of lung cancer (NICE clinical guideline 121) [www.nice.org.uk/guidance/cg121](http://www.nice.org.uk/guidance/cg121) (Last accessed 18/04/2016)

Antoch G, Stattaus J, Nemat AT *et al.* Non-small-cell lung cancer: dual modality PET/CT in preoperative staging. *Radiology* 2003; **229**: 526–533.

Bryant AS, Cerfolio RJ. The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. *Ann Thorac Surg* 2006; **82**: 1016–1020.

Cerfolio RJ, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. *Chest* 2006; **130**: 1791–1795.

Lardinois D, Weder W, Hany TF *et al.* Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. *N Engl J Med* 2003; **348**: 2500–2507.

Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. *JAMA* 2001; **285**: 914–924.

Baldwin DR, Callister ME on behalf of the members of Guideline Development Group. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. *Thorax* 2015; **70**: 794–798.

McWilliams A, Tammermagi MC, Mayo JR *et al.* Probability of cancer in pulmonary nodules detected on first screening CT. *N Engl J Med* 2013; **369**: 910–919.

Keidar Z, Haim N, Guralnik L *et al.* PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. *J Nucl Med* 2004; **45**: 1640–1646.

Shon IH, O'Doherty MJ, Maisey MN. Positron emission tomography in lung cancer. *Semin Nucl Med* 2002; **32**: 240–271.

Tolosa EM, Harpole L, McCrory DC. Non-invasive staging of non-small cell lung cancer: a review of the current evidence. *Chest* 2003; **123**(1 Suppl): 137S–146S.

He YQ, Gong HL, Deng YF, Li WM. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. *Acta Radiol* 2014; **55**: 309–317.

Lu YY, Chen JH, Liang JA *et al.* 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. *Nucl Med Commun* 2014; **35**: 697–703.

### Pleural malignancy

Treglia G, Sadeghi R, Annunziata S *et al.* Diagnostic accuracy of 18F-FDG PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: a systematic review and meta-analysis. *Acad Radiol* 2014; **21**: 11–20.

Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. *Lung Cancer* 2005; **49**(S1): S27–S32.

Truong MT, Marom EM, Erasmus JJ. Preoperative evaluation of patients with malignant pleural mesothelioma: role of integrated CT-PET imaging. *J Thorac Imaging* 2006; **21**: 146–153.

### Thymic tumours

Benveniste MF, Moran CA, Mawlawi O *et al.* FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. *J Thorac Oncol* 2013; **8**: 502–510.

**Oesophago-gastric carcinoma**

Flanagan FL, Dehdashti F, Siegel BA *et al.* Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. *AJR Am J Roentgenol* 1997; **168**: 417–424.

Gillies RS, Middleton MR, Maynard ND, Bradley KM, Gleeson FV. Additional benefit of 18F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer. *Eur Radiol* 2011; **21**: 274–280.

Kato H, Miyazaki T, Nakajima M *et al.* The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. *Cancer* 2005; **103**: 148–156.

You JJ, Wong RK, Darling G *et al.* Clinical utility of <sup>18</sup>F-FDG PET/CT in the staging of patients with potentially resectable esophageal cancer. *J Thorac Oncol* 2013; **8**: 1563–1569.

Findlay JM, Bradley KM, Maile EJ *et al.* Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy. *Br J Surg* 2015; **102**: 1488–1499.

Findley JM, Gillies RS, Franklin JM *et al.* Restaging oesophageal cancer after neoadjuvant therapy with 18F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery. *Eur Radiol* 2016 Feb 16 [Epub ahead of print].

Teyton P, Metges JP, Atmani A *et al.* Use of positron emission tomography in surgery follow-up of esophageal cancer. *J Gastrointest Surg* 2009; **13**: 451–458.

Thureau K, Palmes D, Franzius C *et al.* Impact of PET-CT on primary staging and response control on multimodal treatment of esophageal cancer. *World J Surg* 2011; **35**: 608–616.

Goense L, van Rossum PS, Reitsma JB *et al.* Diagnostic performance of 18F-FDG PET and PET/CT for the detection of recurrent esophageal cancer after treatment with curative intent: a systematic review and meta-analysis. *J Nucl Med* 2015; **56**: 995–1002.

**Gastrointestinal stromal tumours (GIST)**

Antoch G, Kanja J, Bauer S *et al.* Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib therapy in patients with gastrointestinal stromal tumours. *J Nucl Med* 2004; **45**: 357–365.

Gayed I, Vu T, Iyer R *et al.* The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumours. *J Nucl Med* 2004; **45**: 17–21.

**Breast carcinoma**

Isasi CR, Moadel RM, Blaufox MD *et al.* A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. *Breast Cancer Res Treat* 2005; **90**: 105–112.

Klaeser B, Wiederkehr O, Koeberle D, Mueller A, Bubeck B, Thuerlimann B. Therapeutic impact of 2-[fluorine-18]fluoro-2-deoxy-D glucose positron emission tomography in the pre- and post-operative staging of patients with clinically intermediate or high-risk breast cancer. *Ann Oncol* 2007; **18**: 1329–1334.

Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT and breast cancer imaging. *RadioGraphics* 2007; **27**: S215–S229.

Ng SP, David S, Alamgeer M, Ganju V. Impact of pre-treatment combined FDG PET/CT staging on radiation therapy treatment decisions in locally advanced breast cancer. *Int J Radiat Oncol Biol Phys* 2015; **93**: 111–117.

Gebhart G, Gamez C, Holmes E *et al.* 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. *J Nucl Med* 2013; **54**: 1862–1868.

#### **Hepato-pancreatico-biliary malignancy**

Garcea G, Ling Ong S, Maddern GJ. The current role of PET-CT in the characterization of hepatobiliary malignancies. *HPB* 2009; **11**: 4–17.

Jadvar H, Henderson RW, Conti PS. [F-18]Fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. *J Comput Assist Tomogr* 2007; **31**: 223–228.

Pakzad F, Groves AM, Eil PJ. The role of positron emission tomography in the management of pancreatic cancer. *Semin Nucl Med* 2006; **36**: 248–256.

Petrowsky H, Wildbrett P, Husarik DB *et al.* Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. *J Hepatol* 2006; **45**: 43–50.

#### **Colorectal carcinoma**

Brush J, Boyd K, Chappell F *et al.* The value of FDG PET/CT in pre-operative staging of colorectal carcinoma: a systematic review and economic evaluation. *Health Technol Assess* 2011; **15**: 1–192.

Llamas-Elvira JM, Rodriguez-Fernandez A, Guitierrez-Sainz J *et al.* Fluorine-18 fluorodeoxyglucose PET in the pre operative staging of colorectal cancer. *Eur J Nucl Med Mol Imaging* 2007; **34**: 859–867.

Lake Es, Wadhvani S, Subar D *et al.* The influence of FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis. *Ann R Coll Surg Engl* 2014; **96**: 211–215.

Moulton CA, Gu CS, Law CH *et al.* Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases – a randomized clinical trial. *JAMA* 2014; **311**: 1863–1869.

Maffione AM, Lopci E, Bluemel C *et al.* Diagnostic accuracy and impact on management of (18)F-FDG PET and PET/CT in colorectal liver metastases: a meta-analysis and systematic review. *Eur J Nucl Med Mol Imaging* 2015; **42**: 152–163.

National Institute for Health and Clinical Excellence. *Colorectal cancer: diagnosis and management*. London: National Institute for Health and Care Excellence, 2011.

Calvo FA, Sole CV, de la Mata D *et al.* 18F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes. *Eur J Nucl Med Mol Imaging* 2013; **40**: 657–667.

Huh JW, Kwon SY, Lee JH, Kim HR. Comparison of restaging accuracy of repeat FDG-PET/CT with pelvic MRI after preoperative chemoradiation in patients with rectal cancer. *J Cancer Res Clin Oncol* 2015; **141**: 353–359.

Maffione AM, Marzola MC, Capirci C, Colletti PM, Rubello D. Value of (18)F-FDG PET for predicting response to neoadjuvant therapy in rectal cancer: systematic review and meta-analysis. *AJR Am J Roentgenol* 2015; **204**: 1261–1268.

Bonichon F, Palussière J, Godbert Y *et al.* Diagnostic accuracy of 18F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicentre prospective study. *Eur J Nucl Med Mol Imaging* 2013; **40**: 1817–1827.

Nielsen K, van Tiborg AA, Sheffer HJ *et al.* PET-CT after radiofrequency ablation of colorectal liver metastases: Suggestions for timing and image interpretation. *Eur J Radiol* 2013; **82**: 2169–2175.

Zheng JH, Chang ZH, Han CB *et al.* Detection of residual tumor following radiofrequency ablation of liver metastases using 18F-FDG PET/CT: a systematic review and meta-analysis. *Nucl Med Commun* 2013; **35**: 339–346.

Sabet A, Meyer C, Aouf A *et al.* Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-predominant metastatic colorectal cancer. *Eur J Nucl Med Mol Imaging* 2015; **42**: 370–376.

Lu YY, Chen JH, Chien CR *et al.* Use of FDG-PET or PET/CT to detect recurrent colorectal cancer in patients with elevated CEA: a systematic review and meta-analysis. *Int J Colorectal Dis* 2013; **28**: 1039–1047.

### **Urological Malignancy**

Avril N, Dambha F, Murray I, Shamash J, Powles T, Sahdev A. The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers. *Int J Urol* 2010; **17**: 501–511.

Swinnen G, Maes A, Pottel H *et al.* FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. *Eur Urol* 2010; **57**: 641–647.

Kibel AS, Dehdashti F, Katz *et al.* Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. *J Clin Oncol* 2009; **27**: 4314–4320.

Mertens LS, Mir C, Scott AM *et al.* 18F-fluorodeoxyglucose-positron emission tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. *Urology* 2014; **83**: 393–399.

### **Gynaecological malignancy**

Boughanim M, Leboulleux S, Rey AJ *et al.* Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F] fluorodeoxyglucose positron emission tomography scans in the para-aortic area. *Clin Oncol* 2008; **26**: 2558–2561.

Chao A, Ho K-C, Wang C-C *et al.* PET in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastases. *Gynecol Oncol* 2008; **110**: 172–178.

Chung HH, Kang WJ, Kim JW *et al.* The clinical impact of [(18)F] FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings. *Eur J Nucl Med Mol Imaging* 2008; **35**: 1081–1088.

Grigsby PW. Role of PET in gynecologic malignancy. *Curr Opin Oncol* 2009; **21**(5): 420–424.

Loft A, Berthelsen AK, Roed H *et al.* The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. *Gynaecol Oncol* 2007; **106**: 29–34.

Soussan M, Wartski M, Cherel P *et al.* Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. *Gynecol Oncol* 2008; **108**: 160–165.

Amit A, Person O, Keidar Z. FDG PET/CT in monitoring response to treatment in gynaecological malignancies. *Curr Opin Obstet Gynecol* 2013; **25**: 17–22.

Lee JE, Huh SJ, Nam H, Ju SG. Early response of patients undergoing concurrent chemoradiotherapy for cervical cancer: a comparison of PET/CT and MRI. *Ann Nucl Med* 2013; **27**: 37–45.

Kidd EA, Thomas M, Siegel BA, Dehdashti F, Grigsby PW. Changes in cervical cancer FDG uptake during chemoradiation and association with response. *Int J Radiat Oncol Biol Phys* 2013; **85**: 116–122.

### **Testicular tumours**

De Santis M, Becherer A, Bokemeyer C *et al.* 2-18 fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. *J Clin Oncol* 2004; **22**: 1034–1039.

Huddart RA, O'Doherty MJ, Padhani A *et al.* 18Fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I non seminomatous germ cell tumors: preliminary report of MRC Trial TE22 – the NCRI Testis Tumour Clinical Study Group. *J Clin Oncol* 2007; **25**: 3090–3095.

Oechsle K, Hartmann M, Brenner W *et al.* [18F]fluorodeoxyglucose positron emission tomography in nonseminomatous germ cell tumors after chemotherapy: the German Multicenter Positron Emission Tomography Study Group. *J Clin Oncol* 2008; **26**: 5930–5935.

Ambrosini V, Zucchini G, Nicolini S *et al.* 18F-FDG PET/CT impact on testicular tumours clinical management. *Eur J Nucl Med Mol Imaging* 2014; **41**: 668–673.

Cook GJ, Sohaib A, Huddart RA *et al.* The role of 18F-FDG PET/CT in the management of testicular cancers. *Nucl Med Commun* 2015; **36**: 702–708.

### **Anal and penile carcinoma**

Graafland NM, Leijte JA, Valdés Olmos RA, Hoefnagel CA, Teertstra HJ, Horenblas S. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma. *Eur Urol* 2009; **56**: 339–345.

Leijte JA, Graafland NM, Valdés Olmos RA, van Boven HH, Hoefnagel CA, Horenblas S. Prospective evaluation of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography in staging clinically node-negative patients with penile carcinoma. *BJU Int* 2009; **104**: 640–644.

Nguyen BT, Joon DL, Khoo V *et al.* Assessing the impact of FDG PET in the management of anal cancer. *Radiother Oncol* 2008; **87**: 376–382.

Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and meta-analysis. *Ann Surg Oncol* 2015; **22**: 3574–3581.

### **Lymphoma**

Barrington SF, Mikhaeel NG. When should FDG-PET be used in the modern management of lymphoma? *Br J Haematol* 2014; **164**: 315–328.

Barrington SF, Mikhaeel NG, Kostakoglu L *et al.* Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. *J Clin Oncol* 2014; **32**: 3048–3058.

Cheah CY, Hofman MS, Dickinson M *et al.* Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. *Br J Cancer* 2013; **109**: 312–317.

Cheson BD, Fisher RI, Barrington SF *et al.* Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. *J Clin Oncol* 2014; **32**: 3059–3067.

Dann EJ, Berkahn L, Mashiach T *et al.* Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. *Br J Haematol* 2014; **164**: 694–700.

El-Galaly TC, Mylam KJ, Bøgsted M *et al.* Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. *Am J Hematol* 2014; **89**: 575–580.

Engert A, Haverkamp H, Kobe C *et al.* Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. *Lancet* 2012; **379**: 1791–1799.

Falchi L, Keating MJ, Marom EM *et al.* Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. *Blood* 2014; **123**: 2783–2790.

Follows GA, Ardeshtna KM, Barrington SF *et al.* Guidelines for the first line management of classical Hodgkin lymphoma. *Br J Haematol* 2014; **166**: 34–49.

Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. *J Clin Oncol* 2015; **33**: 1467–1474.

Mamot C, Klingbiel D, Hitz F *et al.* Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). *J Clin Oncol* 2015; **33**: 2523–2529.

Moskowitz CH, Matasar MJ, Zelenetz AD *et al.* Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. *Blood* 2012; **119**: 1665–1670.

Radford J, Illidge T, Counsell N *et al.* Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. *N Engl J Med* 2015; **372**: 1598–1607.

Raemaekers JM, Andre MP, Federico M *et al.* Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. *J Clin Oncol* 2014; **32**: 1188–1194.

Sauter CS, Matasar MJ, Meikle J *et al.* Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. *Blood* 2015; **125**: 2579–2581.

Trotman J, Luminari S, Boussetta S *et al.* Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. *Lancet Haematol* 2014; **1**: e17–e27.



## Myeloma

Bartel TB, Haessler J, Brown TL *et al*. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. *Blood* 2009; **114**: 2068–2076.

Caldarella C, Treglia G, Isgro MA, Treglia I, Giordano A. The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to treatment in patients with multiple myeloma. *Int J Mol Imaging* 2012; **2012**: 175803. 6 pages doi: 10.1155/2012/175803.

Rajkumar SV, Dimopoulos MA, Palumbo A *et al*. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol* 2014; **15**: e538–548.

Lapa C, Lückerath K, Malzahn U *et al*. 18FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. *Oncotarget* 2014; **15**: 7381–7391.

Lu YY, Chen JH, Lin WY *et al*. FDG PET or PET/CT for detecting intramedullary and extramedullary lesions in multiple myeloma: a systematic review and meta-analysis. *Clin Nucl Med* 2012; **37**: 833–837.

Usmani SZ, Mitchell A, Waheed S *et al*. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. *Blood* 2013; **121**: 1819–1823.

Zamagni E, Patriarca F, Nanni C *et al*. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients with up-front autologous transplantation. *Blood* 2011; **118**: 5989–5995.

Zamagni E, Nanni C, Mancuso K *et al*. PET/CT improves the definition of complete response and allows to detect otherwise unidentifiable skeletal progression in multiple myeloma. *Clin Cancer Res* 2015; **21**: 4384–4390.

## Skin

Aukema TS, Valdes Olmos RA, Wouters MW *et al*. Utility of preoperative 18F FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases. *Annals Surg Oncol* 2010; **17**: 2773–2778.

Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. *Semin Nucl Med* 2004; **34**: 242–253.

Mijnhout GS, Hoekstra OS, van Tulder MW, Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in melanoma patients. *Cancer* 2001; **91**: 1530–1542.

Strobel K, Dummer R, Husarik DB, Pérez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. *Radiology* 2007; **244**: 566–574.

Xing Y, Bronstein Y, Ross MI *et al*. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. *J Natl Cancer Inst* 2011; **103**: 129–142.

Bastiaannet E, Uyl-de Groot CA, Brouwers AH *et al*. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. *Ann Surg* 2012; **255**: 771–776.

Subesinghe M, Marples M, Scarsbrook AF, Smith JT. Clinical impact of 18F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience. *Insights Imaging* 2013; **4**: 701–709.

George A, Girault S, Testard A *et al*. The impact of 18F-FDG PET/CT on Merkel cell carcinoma management a retrospective study of 66 scans from a single institution. *Nucl Med Commun* 2014; **35**: 282–290.

Byrne K, Siva S, Chait L *et al.* 15-year experience of 18F-FDG PET imaging in response assessment and restaging after definitive treatment of Merkel cell carcinoma. *J Nucl Med* 2015; **56**: 1328–1333.

Feeney J, Horwitz S, Gönen M, Schoder H. Characterization of T-cell lymphomas by FDG PET/CT. *AJR Am J Roentgenol* 2010; **195**: 333–340.

### **Musculoskeletal**

Nanni C, Marzola MC, Rubello D, Fanti S. Positron emission tomography for the evaluation of soft-tissue sarcomas and bone sarcomas. *Eur J Nucl Med Mol Imaging* 2009; **36**: 1940–1943.

Lakkaraju A, Patel CN, Bradley KM, Scarsbrook AF. PET/CT in primary musculoskeletal tumours: a step forward. *Eur Radiol* 2010; **20**: 2959–2972.

Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ. [18F] FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. *Eur J Nucl Med Mol Imaging* 2009; **36**: 751–757.

Chirindel A, Chaudhury M, Blakeley JO, Wahl R. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization. *J Nucl Med* 2015; **56**: 379–385.

Khiewvan B, Macapinlac HA, Lev D *et al.* The value of 18F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors. *Eur J Nucl Med Mol Imaging* 2014; **41**: 1756–1766.

Fendler WP, Lehmann M, Todica A *et al.* PET response criteria to solid tumors predicts progression-free survival and time to local or distant progression after chemotherapy with regional hyperthermia for soft-tissue sarcoma. *J Nucl Med* 2015; **56**: 530–537.

### **Paraneoplastic syndromes**

Bannas P, Weber C, Derlin T *et al.* 18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis. *Eur Radiol* 2010; **20**: 923–930.

Hadjivassiliou M, Alder SJ, Van Beek EJ *et al.* PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. *Acta Neurol Scand* 2009; **119**: 186–193.

Patel RR, Subramaniam RM, Mandrekar JN *et al.* Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. *Mayo Clin Proc* 2008; **83**: 917–922.

Younes-Mhenni S, Janier MF, Cinotti L *et al.* FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. *Brain* 2004; **127**: 2331–2338.

Vaidyanathan S, Pennington C, Ng CY, Poon FW, Han S. 18F-FDG PET-CT in the evaluation of paraneoplastic syndromes: experience at a regional oncology centre. *Nucl Med Commun* 2012; **33**: 872–880.

Schramm N, Rominger A, Schmidt C *et al.* Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F PET/CT and contrast-enhanced CT. *Eur J Nucl Med Mol Imaging* 2013; **40**: 1014–1024.

Kristensen SB, Hess S, Petersen H, Høiland-Carlsen PF. Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. *Eur J Nucl Med Mol Imaging* 2015; **42**: 2056–2063.



**Carcinoma of unknown primary**

Kwee TC, Basu S, Cheng G, Alavi A. FDG PET/CT in carcinoma of unknown primary. *Eur J Nucl Med Mol Imaging* 2010; **37**: 635–644.

Fencel P, Belohlavek O, Skopalova M, Jaruskova M, Kantorova I, Simonova K. Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary. *Eur J Nucl Med Mol Imaging* 2007; **34**: 1783–1792.

Wang G, Wu Y, Zhang W, Li J, Wu P, Xie C. Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary. *J Med Imaging Radiat Oncol* 2013; **57**: 65–71.

Elboga U, Kervancioğlu S, Sahin E, Basibuyuk M, Celen YZ, Aktolun C. Utility of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of unknown primary. *Int J Clin Exp Pathol* 2014; **7**: 8941–8946.

**Neuroendocrine carcinoma**

Binderup T, Knigge U, Loft A *et al.* Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. *J Nucl Med* 2010; **51**: 704–712.

Takeuchi S, Balachandran A, Habra MA *et al.* Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients. *Eur J Nucl Med Mol Imaging* 2014; **41**: 2066–2073.

**Rare tumours of children and young adults**

Barrington SF, Begent J, Lynch T *et al.* Guidelines for the use of PET-CT in children. *Nucl Med Commun* 2008; **29**: 418–424.

Bar-Sever Z, Keidar Z, Ben-Barak A *et al.* The incremental value of 18F-FDG PET/CT in paediatric malignancies. *Eur J Nucl Med Mol Imaging* 2007; **34**: 630–637.

Kleis M, Daldrup-Link H, Matthay K *et al.* Diagnostic value of PET/CT for the staging and restaging of pediatric tumors. *Eur J Nucl Med Mol Imaging* 2009; **36**: 23–36.

Meyer JS, Nadel HR, Marina N *et al.* Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. *Pediatr Blood Cancer* 2008; **51**: 163–170.

Misch D, Steffen IG, Schonberger S *et al.* Use of positron emission tomography for staging preoperative response assessment and post therapeutic evaluation in children with Wilms tumour. *Eur J Nucl Med Mol Imaging* 2008; **35**: 1642–1650.

Stauss J, Franzius C, Pfluger T *et al.* European Association of Nuclear Medicine. Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology. *Eur J Nucl Med Mol Imaging* 2008; **35**: 1581–1588. Erratum in: *Eur J Nucl Med Mol Imaging* 2008; **35**: 2140.

Wegner EA, Barrington SF, Kingston JE *et al.* The impact of PET scanning on management of paediatric oncology patients. *Eur J Nucl Med Mol Imaging* 2005; **32**: 23–30.

Quartuccio N, Fox J, Kuk D *et al.* Pediatric bone sarcoma: diagnostic performance of 18F-FDG PET/CT versus conventional imaging for initial staging and follow-up. *AJR Am J Roentgenol* 2015; **204**: 153–160.

Dhull VS, Sharma P, Patel C *et al.* Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy. *Nucl Med Commun* 2015; **36**: 1007–1013.

Norman G, Fayer D, Lewis-Light K *et al.* An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review. *BMJ Open* 2015; **5**: e006030. doi: 10.1136/bmjopen-2014-006030.

### Neurological applications

Foster NL, Heidebrink JL, Clark CM *et al.* FDG-PET improves accuracy in distinguishing fronto-temporal dementia and Alzheimer's Disease. *Brain* 2007; **130**: 2616–2635.

Herholz K, Carter SF, Jones M. Positron emission tomography imaging in dementia. *BJR* 2007; S160–S167.

Hoffman JM, Welsh-Bohmer KA, Hanson M *et al.* FDG PET imaging in patients with pathologically verified dementia. *J Nucl Med* 2000; **41**: 1920–1928.

Ia FC, Rominger A, Forster S, Geisler J, Bartenstein P. PET and SPECT in epilepsy: a critical review. *Epilepsy Behav* 2009; **15**: 50–55.

Lerner JT, Salamon N, Hauptman JS *et al.* Assessment and surgical outcomes for mild type I and severe type II cortical dysplasia: a critical review and the UCLA experience. *Epilepsia* 2009; **50**: 1310–1313.

O'Brien TJ, Miles K, Ware R, Cook MJ, Binns DS, Hicks RJ. The cost-effective use of 18F-FDG PET in the presurgical evaluation of medically refractory focal epilepsy. *J Nucl Med* 2008; **49**: 931–937.

Willmann O, Wennberg R, May T, Woermann FG, Pohlmann-Eden B. The contribution of 18F-FDG PET in preoperative epilepsy surgery evaluation for patients with temporal lobe epilepsy: A meta-analysis. *Seizure* 2007; **16**: 509–520.

### Cardiological applications

Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. *J Am Coll Cardiol* 2002; **39**: 1151–1158.

Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: role of positron emission tomography. *Eur Heart J* 2010; **31**: 2984–2995.

Schinkel AF, Bax JJ, Delgado V, Poldermans D, Rahimtoola SH. Clinical relevance of hibernating myocardium in ischemic left ventricular dysfunction. *Am J Med* 2010; **123**: 978–986.

### Vasculitis

Besson FL, Parienti JJ, Bienvenu B, Prior JO, Costo S, Bouvard G, Agostini D. Diagnostic performance of (18)F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging* 2011; **38**: 1764–1772.

Dasgupta B, Hassan N. British Society for Rheumatology Guidelines Group. Giant cell arteritis: recent advances and guidelines for management. *Clin Exp Rheumatol* 2007; **25**: S62–S65.

### Sarcoidosis

Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F FDG PET/CT in sarcoidosis management: review and report of 20 cases. *Eur J Nucl Med Mol Imaging* 2008; **35**: 1537–1543.

Treglia G, Taralli S, Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. *Sarcoidosis Vasc Diffuse Lung Dis* 2011; **28**: 87–94.

Youssef G, Leung E, Mylonas I et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and meta-analysis including the Ontario experience. *J Nucl Med* 2012; **53**: 241–248.

### **Infection imaging**

Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A. Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. *Semin Nucl Med* 2009; **39**: 36–51.

O'Doherty MJ, Barrington SF, Klein JL. Opportunistic infection and nuclear medicine. *Semin Nucl Med* 2009; **39**: 88–102.

Graziosi M, Nanni C, Lorenzini M et al. Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. *Eur J Nucl Med Mol Imaging* 2014; **41**: 1617–1623.

Ahmed FZ, James J, Cunningham C et al. Early diagnosis of cardiac implantable electronic device generator pocket infection using 18F-FDG PET/CT. *Eur Heart J Cardiovasc Imaging* 2015; **16**: 521–530.

### **Pyrexia of unknown origin (PUO)**

Jasper N, Dbritz J, Frosch M, Loeffler M, Weckesser M, Foell D. Diagnostic value of [(18)F]-FDG PET/CT in children with fever of unknown origin or unexplained signs of inflammation. *Eur J Nucl Med Mol Imaging* 2010; **37**: 136–145.

Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of 18F-FDG PET/CT. *J Nucl Med* 2008; **49**: 1980–1985.

Dong MJ, Zhao K, Liu ZF, Wang GI, Yang SY, Zhou GJ. A meta-analysis of the value of fluorodeoxyglucose-PET/PET-CT in the evaluation of fever of unknown origin. *Eur J Radiol* 2011; **80**: 834–844.

Jamar F, Buscombe J, Chiti A et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. *J Nucl Med* 2013; **54**: 647–658.

Hau R, Yuan L, Kan Y, Li C, Yang J. Diagnostic performance of 18F-FDG PET/CT in patients with fever of unknown origin: a meta-analysis. *Nucl Med Commun* 2013; **34**: 682–688.

## **Indications for non-FDG scans**

### **11C-Methionine – brain**

DeWitte O, Goldberg I, Wikler D et al. Positron emission tomography with injection of methionine as a prognostic factor in glioma. *J Neurosurg* 2001; **95**: 746–750.

Herholz K, Holzer T, Bauer B et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. *Neurology* 1998; **50**: 1316–1322.

Pirotte B, Goldman S, Dewitte O et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. *J Neurosurg* 2006; **104**: 238–253.

Pirotte BJ, Levivier M, Goldman S et al. Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients. *Neurosurgery* 2009; **64**: 471–481.

Pirotte BJ, Lubansu A, Massager N et al. Clinical impact of integrating positron emission tomography during surgery in 85 children with brain tumors. *J Neurosurg Pediatr* 2010; **5**: 486–499.

Smits A, Westerberg E, Ribom D. Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas. *Eur J Nucl Med Mol Imaging* 2008; **35**: 65–71.

Yamane T, Sakamoto S, Senda M. Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm. *Eur J Nucl Med Mol Imaging* 2010; **37**: 685–690.

#### **18F-Fluoroethyltyrosine – brain**

Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. *Neuro Oncol* 2016; **18**: 426–434.

Grosu AL, Astner ST, Riedel E *et al.* An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. *Int J Radiat Oncol Biol Phys* 2011; **81**: 1049–1058.

#### **11C-Methionine – parathyroid**

Beggs AD, Hain SF. Localization of parathyroid adenomas using 11C-methionine positron emission tomography. *Nucl Med Commun* 2005; **26**: 133–136.

Cook GJ, Wong JC, Smellie WJ, Young AE, Maisey MN, Fogelman I. [11C] Methionine positron emission tomography for patients with persistent or recurrent hyperparathyroidism after surgery. *Eur J Endocrinol* 1998; **139**: 195–197.

Hellman P, Ahlström H, Bergström M *et al.* Positron emission tomography with 11C-methionine in hyperparathyroidism. *Surgery* 1994; **116**: 974–981.

Hessman O, Stålberg P, Sundin A *et al.* High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. *World J Surg* 2008; **32**: 774–781.

Otto D, Boerner AR, Hofmann M *et al.* Pre-operative localisation of hyperfunctional parathyroid tissue with 11C-methionine PET. *Eur J Nucl Med Mol Imaging* 2004; **31**: 1405–1412.

Rubello D, Fanti S, Nanni C *et al.* 11C-methionine PET/CT in 99mTc-sestamibi-negative hyperparathyroidism in patients with renal failure on chronic haemodialysis. *Eur J Nucl Med Mol Imaging* 2006; **33**: 453–459.

Sundin A, Johansson C, Hellman P *et al.* PET and parathyroid L-[carbon-11]methionine accumulation in hyperparathyroidism. *J Nucl Med* 1996; **37**: 1766–1770.

Tang BN, Moreno-Reyes R, Blocklet D *et al.* Accurate pre-operative localization of pathological parathyroid glands using 11C-methionine PET/CT. *Contrast Media Mol Imaging* 2008; **3**: 157–163.

Weber T, Maier-Funk C, Ohlhauser D *et al.* Accurate preoperative localization of parathyroid adenomas with C-11 methionine PET/CT. *Ann Surg* 2013; **257**: 1124–1128.

#### **13N-Ammonia and 82Rb – myocardial perfusion imaging**

Di Carli MF, Dorbala S, Curillova Z *et al.* Relationship between CT coronary angiography and stress perfusion imaging in patients with suspected ischemic heart disease assessed by integrated PET-CT imaging. *J Nucl Cardiol* 2007; **4**: 799–809.

Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: role of positron emission tomography. *Eur Heart J* 2010; **31**: 2984–2995.

Groves AM, Speechly-Dick ME, Dickson JC *et al.* Cardiac 82Rubidium PET/CT: initial European experience. *Eur J Nucl Med Mol Imaging* 2007; **34**: 1965–1972.

Lortie M, Beanlands RS, Yoshinaga K, Klein R, Dasilva JN, DeKemp RA. Quantification of myocardial blood flow with <sup>82</sup>Rb dynamic PET imaging. *Eur J Nucl Med Mol Imaging* 2007; **34**: 1765–1774.

Nandalur KR, Dwamena BA, Choudhri AF, Nandalur SR, Reddy P, Carlos RC. Diagnostic performance of positron emission tomography in the detection of coronary artery disease: a meta-analysis. *Acad Radiol* 2008; **15**: 444–451.

#### **11C-Choline or 18F-fluorocholine – prostate cancer**

Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. *Prostate Cancer Prostatic Dis* 2012; **15**: 45–55.

Beheshti M, Imamovic L, Broinger G *et al.* 18 F Choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. *Radiology* 2010; **254**: 925–933.

Castellucci P, Fuccio C, Rubello D *et al.* Is there a role for <sup>11</sup>C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? *Eur J Nucl Med Mol Imaging* 2011; **38**: 55–56.

Castellucci P, Fuccio C, Nanni C *et al.* Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. *J Nucl Med* 2009; **50**: 1394–1400. Erratum in: *J Nucl Med* 2009; **50**(10): 1578.

Cimitan M, Evangelista L, Hodolic M *et al.* Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients. *J Nucl Med* 2015; **56**: 209–215. Erratum in: *J Nucl Med* 2015; **56**(6): 967.

Beheshti M, Haim S, Zakavi R *et al.* Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. *J Nucl Med* 2013; **54**: 833–840.

Jadvar H. Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline. *J Nucl Med* 2011; **52**: 81–89.

Kwee SA, Coel MN, Lim J *et al.* Prostate cancer localisation with 18-Fluorine fluorocholine positron emission tomography. *J Urol* 2005; **173**: 252–255.

Kwee SA, Wei H, Sesterhenn I *et al.* Localisation of primary prostate cancer with dual-phase 18F-fluorocholine PET. *J Nucl Med* 2006; **47**: 262–269.

Rodado-Marina S, Coronado-Poggio M, García-Vincente AM *et al.* Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study. *BJU Int* 2015; **115**: 874–883.

Picchio M, Briganti A, Fanti S *et al.* The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. *Eur Urol* 2011; **59**: 51–60.

Reske SN, Blumstein NM, Neumaier B *et al.* Imaging prostate cancer with C11-Choline PET/CT. *J Nucl Med* 2006; **47**: 1249–1254.

Scattoni V, Picchio M, Suardi N *et al.* Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. *Eur Urol* 2007; **52**: 423–429.

Scher B, Seitz M, Albinger W *et al.* Value of C-11-choline PET and PET/CT in patients with suspected prostate cancer. *Eur J Nucl Med Mol Imaging* 2007; **34**: 45–53.

Castellucci P, Ceci F, Graziani T *et al.* Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? *J Nucl Med* 2014; **55**: 1424–1429.

Chondrogiannis S, Marzola MC, Ferretti A *et al.* Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy? *Eur J Nucl Med Mol Imaging* 2014; **41**: 1293–1300.

#### **68Ga-PSMA – prostate cancer**

Eiber M, Maurer T, Souvatzoglou M *et al.* Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. *J Nucl Med* 2015; **56**: 668–674.

Morigi JJ, Stricker PD, van Leeuwen PJ *et al.* Prospective Comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. *J Nucl Med* 2015; **56**: 1185–1190.

Budäus L, Leyh-Bannurah SR, Salomon G *et al.* Initial experience of (68)Ga-PSMA PET/ct imaging in high-risk prostate cancer patients prior to radical prostatectomy. *Eur Urol* 2016; **69**: 393–396.

Afshar-Oromieh A, Zechmann CM, Malcher A *et al.* Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging* 2014; **41**: 11–20.

Afshar-Oromieh A, Avtzi E, Giesel FL *et al.* The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging* 2015; **42**: 197–209.

Afshar-Oromieh A, Malcher A, Eder M *et al.* PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. *Eur J Nucl Med Mol Imaging* 2013; **40**: 486–495.

Afshar-Oromieh A, Haberkorn U, Eder M *et al.* [68Ga]gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. *Eur J Nucl Med Mol Imaging* 2012; **39**: 1085–1086.

#### **11C-choline, 11C-acetate or 18F-fluorocholine – hepatocellular carcinoma**

Khan MA, Combs CS, Brunt EM *et al.* Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. *J Hepatol* 2000; **32**: 792–797.

Mertens K, Slaets D, Lambert B, Acou M, De Vos F, Goethals I. PET with 18F-labelled choline-based tracers for tumour imaging: a review of the literature. *Eur J Nucl Med Mol Imaging* 2010; **37**: 2188–2193.

Park JW, Kim JH, Kim SK *et al.* A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. *J Nucl Med* 2008; **49**: 1912–1921.

Salem N, Kuang Y, Wang F, Maclennan GT, Lee Z. PET imaging of hepatocellular carcinoma with 18F-FDG, 6-deoxy-6[18F]fluoro-D-glucose, [1-11C]-acetate and [N-methyl-11C]-choline. *Q J Nucl Med Mol Imaging* 2009; **53**: 144–156.

Talbot JN, Fartoux L, Balogova S *et al.* Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis and chronic liver disease. *J Nucl Med* 2010; **51**: 1699–1706.



Salem N, Kuang Y, Corn D *et al.* [(Methyl)<sup>11</sup>C]-Acetate metabolism in hepatocellular carcinoma. *Mol Imaging Biol* 2011; **13**: 140–151.

Yamamoto Y, Nishiyama Y, Kameyama R *et al.* Detection of hepatocellular carcinoma using <sup>11</sup>C-choline PET: comparison with <sup>18</sup>F-FDG PET. *J Nucl Med* 2008; **49**: 1245–1248.

Bertagna F, Bertoli M, Bosio G *et al.* Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis. *Hepatol Int* 2014; **8**: 493–500.

#### **68Ga-labelled somatostatin receptor (SSR) imaging**

Ambrosini V, Tomassetti P, Castellucci P *et al.* Comparison between Gallium-68 DOTANOC and Fluorine-18 DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. *Eur J Nucl Med Mol Imaging* 2008; **35**: 1431–1438.

Ambrosini V, Campana D, Bodei L *et al.* 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. *J Nucl Med* 2010; **51**: 669–673.

Baum RP, Prasad V, Hoffmann M, Horsch D. Receptor PET/CT imaging of neuroendocrine tumours. *Recent Results Cancer Res* 2008; **170**: 225–242.

Breeman WAP, de Blois E, Chan HS, Konijnenberg M, Kwekkeboom DJ, Krenning EP. 68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. *Semin Nucl Med* 2011; **41**: 314–321.

Kayani I, Bomanji JB, Groves A *et al.* Functional imaging of neuroendocrine tumours with combined PET/CT using Gallium-68 DOTATATE and Fluorine-18 FDG. *Cancer* 2008; **112**: 2447–2455.

Kowalski J, Henze M, Schuhmacher K *et al.* Evaluation of positron emission tomography imaging using Gallium-68 DOTATOC in comparison to Indium-111 DTPA-Octreotide SPECT. *Mol Imaging Biol* 2003; **5**: 42–48.

Virgolini I, Ambrosini V, Bomanji JB *et al.* Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. *Eur J Nucl Med Mol Imaging* 2010; **37**: 2004–2010.

Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging* 2013; **40**: 1770–1780.

Herrmann K, Czernin J, Wolin EM *et al.* Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. *J Nucl Med* 2015; **56**: 70–75.

#### **18F-DOPA**

Dudczak R, Traub-Weidinger T. PET and PET/CT in endocrine tumours. *Eur J Radiol* 2010; **73**: 481–493.

Koopmans KP, Neels OC, Kema IP *et al.* Improved staging of patients with carcinoid and islet cell tumors with <sup>18</sup>F-dihydroxy-phenyl-alanine and <sup>11</sup>C-5-hydroxy-tryptophan positron emission tomography. *J Clin Oncol* 2008; **26**: 1489–1495.

Taieb D, Tessonnier L, Sebag F *et al.* The role of <sup>18</sup>F-FDOPA and <sup>18</sup>F-FDG-PET in the management of malignant and multifocal pheochromocytomas. *Clin Endocrinol* 2008; **69**: 580–586.

Veit-Haibach P, Schiesser M, Soyka J *et al.* Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component. *Eur Radiol* 2011; **21**: 256–264.

View Schiesser M, Veit-Haibach P, Muller MK *et al.* Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours. *Br J Surg* 2010; **97**: 691–697.

Zani A, Nah SA, Ron O *et al.* The predictive value of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy. *J Pediatr Surg* 2011; **46**: 204–208.

Meintjes M, Endozo R, Dickson J *et al.* 18F-DOPA PET and enhanced CT imaging for congenital hyperinsulinism: initial UK experience from a technologist's perspective. *Nucl Med Commun* 2013; **34**: 601–608.

Yang J, Hao R, Zhu X. Diagnostic role of 18F-dihydroxyphenylalanine positron emission tomography in patients with congenital hyperinsulinism: a meta-analysis. *Nucl Med Commun* 2013; **34**: 347–353.

### **18F-fluoride bone imaging**

Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT. *J Nucl Med* 2006; **47**: 287–297.

Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-Fluoride: applying new technology to an old tracer. *J Nucl Med* 2008; **49**: 68–70.

Segall G, Delbeke D, Stabin MG *et al.* SNM practice guideline for sodium 18F-Fluoride PET/CT bone scans 1.0. *J Nucl Med* 2010; **51**: 1813–1820.

Beheshti M, Mottaghy FM, Payche F *et al.* F-NaF PET/CT: EANM procedure guidelines for bone imaging. *Eur J Nucl Med Mol Imaging* 2015; **42**: 1767–1777.

Hillner BE, Siegel BA, Hanna L *et al.* 18F-Fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. *J Nucl Med* 2015; **56**: 222–228.

Shen CT, Qiu ZI, Han TT *et al.* Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: a meta-analysis. *Clin Nucl Med* 2015; **40**: 103–110.

### **18F-Florbetapir, 18F-Florbetaben, 18F-Flutemetamol**

Clark CM, Schneider JA, Bedell BJ *et al.* Use of florbetapir-PET for imaging  $\beta$ -amyloid pathology. *JAMA* 2011; **305**: 275–283.

Clark CM, Pontecorvo MJ, Beach TG *et al.* Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid- $\beta$  plaques: a prospective cohort study. *Lancet Neurol* 2012; **11**: 669–678.

Wong DF, Rosenberg PB, Zhou Y *et al.* In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir F-18). *J Nucl Med* 2010; **51**: 913–920.

Johnson KA, Minoshima S, Bohnen NI *et al.* Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. *J Nucl Med* 2013; **54**: 476–490.

Thal DR, Beach TG, Zanjetti M *et al.* 18F-Flutemetamol amyloid PET in pre-clinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid pathology. *Alzheimers Dement* 2015; **11**: 975–985.

Ossenkoppele R, Jansen WJ, Rabinovici R *et al.* Prevalence of amyloid PET Positivity in dementia syndromes: a meta-analysis. *JAMA* 2015; **313**: 1939–1949.



Sabri O, Sabbagh MN, Seibyl J *et al.* Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. *Alzheimers Dement* 2015; **11**: 964–974.

**Front cover:**

Images from patients using:

18F-fluoride for breast cancer, 18F-ethyl tyrosine for glioma, 18F-choline for prostate cancer

18F-FDG for assessing an infected pacemaker

68Ga-PSMA for prostate cancer

18F-FDG for soft tissue sarcoma in a child

## Citation details

Royal College of Physicians of London, Royal College of Physicians and Surgeons of Glasgow, Royal College of Physicians of Edinburgh, The Royal College of Radiologists, British Nuclear Medicine Society, Administration of Radioactive Substances Advisory Committee. *Evidence-based indications for the use of PET-CT in the United Kingdom 2016*. London: The Royal College of Radiologists, 2016.

Ref No. BFCR(16)3

© The Royal College of Radiologists, May 2016.

For permission to reproduce any of the content contained herein, please email: [permissions@rcr.ac.uk](mailto:permissions@rcr.ac.uk)

This material has been produced by Royal College of Physicians of London, Royal College of Physicians and Surgeons of Glasgow, Royal College of Physicians of Edinburgh, The Royal College of Radiologists, British Nuclear Medicine Society, Administration of Radioactive Substances Advisory Committee for use internally within the specialties of clinical oncology and clinical radiology in the United Kingdom. It is provided for use by appropriately qualified professionals, and the making of any decision regarding the applicability and suitability of the material in any particular circumstance is subject to the user's professional judgement.

While every reasonable care has been taken to ensure the accuracy of the material, RCR cannot accept any responsibility for any action taken, or not taken, on the basis of it. As publisher, RCR shall not be liable to any person for any loss or damage, which may arise from the use of any of the material. The RCR does not exclude or limit liability for death or personal injury to the extent only that the same arises as a result of the negligence of RCR, its employees, Officers, members and Fellows, or any other person contributing to the formulation of the material.

### **The Royal College of Radiologists**

63 Lincoln's Inn Fields, London WC2A 3JW

**Tel:** +44 (0)20 7405 1282

**Email:** [enquiries@rcr.ac.uk](mailto:enquiries@rcr.ac.uk) [www.rcr.ac.uk](http://www.rcr.ac.uk)

A Charity registered with the Charity Commission No. 211540